Nortriptyline
| Evidence Level: L2 | Predicted Indications: 2 |
Table of Contents
Nortriptyline: Attention deficit-hyperactivity disorder
One-Sentence Summary
Nortriptyline is a tricyclic antidepressant, with original indications of anxiety disorder, neurotic disorder and dysthymic disorder. The TxGNN model predicts it may be effective for attention deficit-hyperactivity disorder (ADHD). Currently there are no registered clinical trials, but 15 publications were retrieved, including a Cochrane review and a controlled trial in children and adolescents.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Attention deficit-hyperactivity disorder |
| TxGNN Prediction Score | 0.9942 |
| Evidence Level | L2 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known class pharmacology, nortriptyline is a tricyclic antidepressant that mainly inhibits norepinephrine reuptake, with weaker serotonin reuptake inhibition. A PET study in patients with depression (PMID 24345533) also examined norepinephrine transporter occupancy by nortriptyline.
Noradrenergic enhancement in prefrontal circuits is the shared mechanism of approved non-stimulant ADHD drugs such as atomoxetine. A review of non-stimulant ADHD treatments (PMID 15064003) notes that these compounds share noradrenergic/dopaminergic activity. It also identifies the secondary-amine tricyclics, including nortriptyline, as established alternative treatments.
The original indications (anxiety, neurotic and dysthymic disorders) and ADHD are all psychiatric conditions, and ADHD often co-occurs with mood and anxiety disorders. The prediction is therefore biologically plausible. Its clinical use is limited by a narrow therapeutic index, cardiac conduction effects, anticholinergic effects and overdose toxicity.
A second predicted indication, ADHD inattentive type (score 0.9933), is a subtype of the same condition. It has no supporting trials or literature and is rated L4 / Hold. It is not evaluated further here.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25238582 | 2014 | Cochrane systematic review | Cochrane Database Syst Rev | Reviews tricyclic antidepressants as second-line treatment for ADHD in children and adolescents |
| 11052409 | 2000 | RCT | J Child Adolesc Psychopharmacol | Controlled study of nortriptyline efficacy and tolerability in pediatric ADHD |
| 22700161 | 2012 | Randomized double-blind trial | Pediatr Nephrol | Nortriptyline for enuresis in children with ADHD |
| 15064003 | 2004 | Review | Psychiatr Clin North Am | Non-stimulant treatments for adult ADHD; nortriptyline and desipramine are the more noradrenergic tricyclics, but a narrow therapeutic index and cardiovascular toxicity limit their use |
| 12270803 | 2002 | Review | Adolesc Med | Lists nortriptyline among tricyclics effective for ADHD in adolescents |
| 22303520 | 2012 | Guideline | Ann Clin Psychiatry | CANMAT recommendations for mood disorders with comorbid ADHD |
| 8428873 | 1993 | Open-label/cohort | J Am Acad Child Adolesc Psychiatry | Nortriptyline in children with ADHD and tic disorder or Tourette’s syndrome |
| 8444763 | 1993 | Chart review | J Am Acad Child Adolesc Psychiatry | Chart review of 58 children and adolescents with ADHD treated with nortriptyline |
| 8444754 | 1993 | Retrospective study | J Am Acad Child Adolesc Psychiatry | Serum levels and ECG effects of nortriptyline in children and adolescents |
| 4075308 | 1985 | Early clinical report | Clin Neuropharmacol | Early report of nortriptyline in attention deficit disorder |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 158104 | Norhap 25mg Tablet | Strip of 10 tablets | Not stated in the data |
| 151869 | Nordep 25mg Tablet | Strip of 10 tablets | Not stated in the data |
| 229119 | Tyval 75mg Tablet | Strip of 10 tablets | Not stated in the data |
| 158368 | Notrima 25mg Tablet | Strip of 10 tablets | Not stated in the data |
| 232875 | Unotrip 15mg Tablet | Strip of 10 tablets | Not stated in the data |
There are 20 valid single-ingredient licences in total (all oral tablets); the five main ones are shown.
Safety Considerations
- Contraindications (knowledge graph, not label text):
- Cardiac: long QT syndrome, familial long QT syndrome, torsades de pointes, myocardial infarction, coronary thrombosis, sudden cardiac arrest, heart conduction disease
- Cerebrovascular: stroke, cerebrovascular disorder, cerebral infarction
- Neuropsychiatric: epilepsy, manic bipolar affective disorder, substance abuse/dependence
- Ocular and urological: open-angle glaucoma, glaucoma, benign prostatic hyperplasia
- Thyroid: hyperthyroidism, Graves disease, thyrotoxicosis
- Organ failure and blood: liver failure, kidney failure, uremia, hemoglobinopathy
- Drug Interactions: 295 interactions recorded. Major-level examples include epinephrine, bupropion, lorcaserin, potassium citrate and dolasetron. Moderate-level examples include famotidine, cimetidine, clarithromycin, morphine, and anticholinergics such as atropine, hyoscyamine, glycopyrronium and dicyclomine. CYP2D6-related interactions are also relevant.
- Class-related concerns: Cardiac conduction effects (QTc/PR prolongation), anticholinergic effects and overdose toxicity. In children, the ECG effects of nortriptyline have been examined (PMID 8444754).
Please refer to the package insert for label-based warnings, as these were not available for this report.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The evidence rests on one controlled trial (PMID 11052409), a Cochrane review of tricyclics, and several reviews and observational studies. These support efficacy in ADHD, but no registered trials back the indication. The cardiac and interaction risks are substantial, so any further work needs strict safety guardrails.
To proceed, the following is needed:
- India package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism of action data from DrugBank
- Cardiac screening plan (baseline and follow-up ECG) and exclusion of patients with the contraindicated conditions listed above
- Interaction management plan, especially for CYP2D6 inhibitors and QT-prolonging drugs
- Confirmation of efficacy in adults, and of the practical role of nortriptyline relative to approved non-stimulants such as atomoxetine
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.